That is one of the synergistic potentials that SS and many others here are referring to about pona including those patents that are in the shelf (neurological disorders, et al) waiting for clinical trials if and when resources become available. While 113 is as equally good, pona is the one earning the revenues now until 113 goes to production 2/3 years from now.
News 
Market Data 
Discover 
